Esperion Therapeutic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Esperion therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Esperion Therapeutic Today - Breaking & Trending Today

Esperion Therapeutics' (ESPR) "Buy" Rating Reiterated at HC Wainwright

Esperion Therapeutics' (ESPR) "Buy" Rating Reiterated at HC Wainwright
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Esperion Therapeutics Company Profile , Vanguard Group Inc , Esperion Therapeutics Inc , Armistice Capital , Capital Partners , Needham Company , Esperion Therapeutics , Free Report , Esperion Therapeutic , Moderate Buy , Get Free Report , Asset Management , Wasatch Advisors , Esperion Therapeutics Daily ,

Q1 2026 Earnings Estimate for Esperion Therapeutics, Inc. Issued By Zacks Research (NASDAQ:ESPR)

Q1 2026 Earnings Estimate for Esperion Therapeutics, Inc. Issued By Zacks Research (NASDAQ:ESPR)
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Zacks Research , Needham Company , Esperion Therapeutics Inc , Esperion Therapeutics Company Profile , Connor Clark Lunn Investment Management Ltd , Armistice Capital , Capital Partners , Esperion Therapeutics , Free Report , Esperion Therapeutic , Therapeutics Stock Down , Get Free Report , Asset Management , Connor Clark , Lunn Investment Management , Esperion Therapeutics Daily ,

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Expected to Earn FY2026 Earnings of $1.44 Per Share

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Expected to Earn FY2026 Earnings of $1.44 Per Share
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United States , Esperion Therapeutics Company Profile , Portfolio Partners , Herbst Group , Chicago Partners Investment Group , Zacks Research , Needham Company , Simplicity Wealth , Esperion Therapeutics Inc , Esperion Therapeutics , Free Report , Esperion Therapeutic , Get Free Report , Partners Investment Group , Esperion Therapeutics Daily ,

Q4 2025 Earnings Forecast for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Issued By Zacks Research

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Investment analysts at Zacks Research cut their Q4 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued on Monday, April 29th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will earn $0.14 per share for the quarter, […] ....

United States , Esperion Therapeutics Inc , Simplicity Solutions , Connor Clark Lunn Investment Management Ltd , Esperion Therapeutics Company Profile , Zacks Research , Capital Partners , Needham Company , Pinnacle Associates Ltd , Esperion Therapeutics , Free Report , Esperion Therapeutic , Get Free Report , Lunn Investment Management , Pinnacle Associates , Esperion Therapeutics Daily , Nasdaq Espr , Earnings Estimates ,

HC Wainwright Reaffirms "Buy" Rating for Esperion Therapeutics (NASDAQ:ESPR)

HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Esperion Therapeutics’ FY2026 earnings at $2.50 EPS, FY2027 earnings at […] ....

United States , Esperion Therapeutics Inc , Royal Bank , Prelude Capital Management , Barclays Plc , Needham Company , Capital Partners , Vanguard Group Inc , Esperion Therapeutics , Free Report , Esperion Therapeutic , Get Free Report , Capital Management , Esperion Therapeutics Daily , Nasdaq Espr , Reiterated Rating , Hc Wainwright ,